Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Galapagos Islands -- Ignore unavailable to you. Want to Upgrade?

To: Jorj X Mckie who wrote (32088)	3/12/2003 12:57:41 PM
From: NOW	Read Replies (1) \| Respond to of 57110

OPEX date? FWIW Bradley turn tommorow then again minor turn 3/28 into 4/11

To: Jorj X Mckie who wrote (32088)	3/12/2003 3:14:36 PM
From: tuck	Respond to of 57110

Well it worked. Bought some 24 cubes which I just sold for a ~30% gain. But it was a small position, so after costs . . . paid for groceries this month. Trying to flip to cube puts now. On the biotech front, The Street.scum put out an article that cost DNA stock two bucks yesterday. Said 7 folks in the Avastin trial had bowel perforations, as if this might be the fault of the drug. The trial was for colorectal cancer, and guess what? Colonoscopies -- the best screening procedures for colorectal cancer -- result in 2 perforations per thousand procedures. The company didn't specifically say that was the cause, and in fact, I can't find out if they were doing colonoscopies, but I would think so. Anyhow, last I looked, the stock hadn't recovered from that low blow. Possible trading opportunity if folks come to their senses. It is highly unlikely that an anti VEGF Mab will cause such a thing. Use your charts, I don't follow DNA that closely, so can't pass much fundamental judgement, either. Cheers, Tuck